Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

Genmab A/S announced today it has regained all rights to the HuMax-TAC™ antibody from Merck Serono following a portfolio review by Merck Serono

COPENHAGEN, Denmark | August 2, 2007 | Genmab A/S (OMX: GEN) announced today it has regained all rights to the HuMax-TAC™ antibody from Merck Serono following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously licensed to Merck Serono in May 2005. Regaining the rights to HuMax-TAC will not influence Genmab’s financial guidance for 2007.

“Now that we have regained rights to the HuMax-TAC program, Genmab will review the program internally to decide on future plans,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.SOURCE: Genmab A/S

Post Views: 198